Are child-centric aspects in newborn and child health systematic review and meta-analysis protocols and reports adequately reported?—two systematic reviews by unknown
RESEARCH Open Access
Are child-centric aspects in newborn and
child health systematic review and meta-
analysis protocols and reports adequately
reported?—two systematic reviews
Mufiza Farid-Kapadia1*†, Kariym C. Joachim1†, Chrinna Balasingham1, April Clyburne-Sherin1 and Martin Offringa1,2
Abstract
Background: Evidence suggests that newborn and child health systematic reviews and meta-analyses exhibit poor
quality in reporting. The “Preferred Reporting Items in Systematic Review and Meta-Analysis” (PRISMA) and PRISMA-
Protocols (PRISMA-P) checklists have been developed to improve the reporting of systematic review results and
protocols, respectively. We aimed to evaluate the clarity and transparency in reporting of child-centric items in child
health systematic reviews (SRs) and SR protocols and to identify areas where reporting could be strengthened.
Methods: Two preliminary lists of potential child-centric reporting items were used to examine current reporting.
The Cochrane, DARE, MEDLINE, and EMBASE libraries were searched from 2010 to 2014 for systematic reviews that
included children. Each report and protocol that met the inclusion criteria had their quality of reporting assessed by
their reporting of child-centric items. Quality of reporting was assessed per whether one third, one to two thirds, or
more than two thirds of papers complied with potential child-centric potential modifications/extensions to PRISMA
and were analyzed by the following: (i) paper type (i.e., report vs. protocol), (ii) publication type (i.e., Cochrane vs.
non-Cochrane), and (iii) population type (i.e., child-only vs. mixed populations vs. family/maternal).
Results: Of the 414 eligible articles, 248 reports and 76 protocols were included. In 21 of 24 potential SR reporting
items and 13 of 14 potential SR protocol reporting items, less than two thirds of papers met the child-centric reporting
item requirements. Mixed population studies displayed significantly poorer reporting in comparison to child-only and
family/maternal intervention studies for 11 potential SR reporting items (p < 0.05) and five potential SR protocol items
(p < 0.05). When comparing non-Cochrane to Cochrane reports and protocols, five items in both lists were found to
perform significantly poorer in non-Cochrane reports (p < 0.05). Significant differences in reporting quality were found
in three of 14 items shared between the potential SR reporting items and potential SR protocol reporting items
(p < 0.05).
Conclusions: Newborn and child health systematic reviews and meta-analyses exhibit incomplete reporting, thereby
hindering prudent decision-making by healthcare providers and policy makers. These results provide a rationale for the
implementation of child-centric extensions and modifications to current PRISMA and PRISMA-P, such as to improve
reporting in this population.
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Background
Systematic reviews (SRs) and meta-analyses (MAs) are
regarded as the highest level of medical evidence [1].
The application of rigorous methodological approaches
for SRs and MAs establish the effectiveness and safety of
interventions in a comprehensive, transparent, and re-
producible nature [2–4]. Unfortunately, evidence shows
that not all SRs are guaranteed to have been performed
with the necessary methodological rigor [5–8]. Evalua-
tions of the methodological quality of large numbers of
SRs have highlighted weaknesses in their design, con-
duct, and reporting, even in high-impact factor journals
[9–12]. Altogether, these weaknesses impair the ability
to transform the results of SRs into practice and policy
guidelines [9, 10].
Steps have been taken to enhance the transparency
and completeness in the reporting of methods and re-
sults of the SRs. In 1996, an international group devel-
oped an SR reporting guideline called the QUOROM
(QUality Of Reporting Of Meta-analyses) Statement
[13], which was followed in 2009 by a guideline update
and renamed to the PRISMA (Preferred Reporting Items
for Systematic reviews and Meta-Analyses) Statement
[14]. Furthering the transparency, consistent conduct,
and replicability of SRs, the PRISMA-Protocols (PRISM
A-P) Statement was created in 2015 [15]. The Inter-
national Prospective Register of Ongoing Systematic
Reviews (PROSPERO) together with PRISMA-P encour-
age the publication of SR protocols to improve processes of
evidence synthesis [15]. Together, PRISMA and PRISMA-P
strive to enhance the ability of stakeholders to critically
appraise and replicate a SRs’ methodology, as well as to in-
terpret its findings for use in health policy decision-making.
A marked increase in the completeness in reporting
of SRs has been reported in journals that endorse
PRISMA [16, 17].
Despite these advances, poor reporting among current
SRs in child health has repeatedly been documented
[7, 18–20]. Given the large degree of physiological,
pharmacological, and psychological differences among
different age groups (e.g., neonates, children, adolescents,
adults, elderly people) [6, 21–23], it is important that
research questions be age-specific and that evidence be
reported in such a way that the resulting recom-
mendations are appropriate for each relevant age
group [19]. This would need to be done for speci-
fied childhood subpopulations [20, 24], describing
age-specific interventions [22, 25], comparators [26],
and outcomes measures [3, 27, 28]. The failure of
SRs and MAs to separately report on research as-
pects which are not uniformly similar across all age
spectrums may impact the ability of decision-makers
to inform policy and program decisions for specific
age groups.
Given that the existing reporting guidelines (i.e., PRISMA
and PRISMA-P) do not encompass the additional reporting
complexities associated with SRs and MAs in child health,
it may be prudent to expand them. While general methodo-
logical items would not be any different for child health SRs
compared to those for other SRs, provision of details that
pertain to child-centric features in clinical research would
make the research to be useful to end-users and decision-
makers. Our recent study on reporting items for child
health clinical trial protocols and reports identified a num-
ber of gaps in relation to transparency, reproducibility,
interpretability, internal and external validity, reporting and
publication bias, accountability, scientific soundness, and re-
search ethics [29]. Many of these issues may also hold true
to child-centric SR protocols and reports. In a recent scop-
ing review, the current authoring team of senior SR authors
identified deficiencies in the reporting of child health SRs
and suggested a number of potential areas where reporting
could be improved [30].
Developing a child health SR reporting standard first
requires assessment of the clarity and transparency in report-
ing the quality of published protocols and SRs to justify and
inform such extensions [31, 32]. In this paper, we report two
SRs that were conducted to examine the need for the devel-
opment of child-centric reporting guideline extensions.
Objective
This study aimed to evaluate the clarity and transpar-
ency in the reporting of child-centric items in child
health SRs and SR protocols and to identify areas where
reporting could be strengthened.
Methods
This review was performed in accordance with the
PRISMA guidelines for SRs [14] (see Additional File 1 for
details) and following a defined protocol, published previ-
ously [31]. This project is not registered with PROSPERO
but, instead, with the Enhancing the QUAlity and Trans-
parency Of health Research (EQUATOR) network [33, 34].
Search strategy
In May of 2015, a literature search of SR reports and
protocols was performed. For the SR on child health SR
reports and protocols, the following databases were
searched for reports; the Cochrane Database of System-
atic Reviews (CDSR) and the Database of Abstracts of
Reviews of Effects (DARE). As both databases have been
filtered to focus on SR reports, only a child search filter
[35] was applied. Since DARE only includes completed
SRs, not protocols, the search strategy was adjusted to
identify child health SR protocols in MEDLINE and
EMBASE databases. Publication date restrictions were
applied from 2010 to 2014 during the literature search
stage (see below), along with restriction to English
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language publications. Our search strategy is reported in
Additional File 2.
Inclusion criteria
We included SR reports and protocols where the tar-
geted population were (i) children, (ii) children and
adults, and (iii) families and mothers as population only
if the outcomes are measured in children. We adopted
the same definitions of “systematic review” and “proto-
col” as set by PRISMA [14] and PRISMA-P [15], respect-
ively. Both reviews were limited to studies published
between 2010 and 2014 following the release and subse-
quent endorsement of the PRISMA Statement in 2009,
which was a benchmark statement in improving the
transparency in reporting of SRs [14]. Any reviews and
protocols focusing on diagnostic evaluation or method-
ology were excluded, as were MAs that did not evaluate
the association of an exposure/intervention with an
outcome.
Screening and full-text extraction
Potentially relevant protocols and reports were de-
duplicated in Endnote X7 [36]. For the initial screening,
the goal was to make sure that children were included in
the titles included in this stage. One reviewer screened
the title and abstract at this stage. The included records
were then exported to Microsoft Excel, and a random
list of titles and abstract was generated in Excel and full
texts were screened until a desired sample size of at least
300 was reached. No SRs were identified not containing
children as (part of ) the population. A data extraction
training exercise was done on 10% of the sample. Four
reviewers did quadruplicate extractions; no discrepancies
occurred. Then, a further 30% of the sample was double
extracted; this did not yield any relevant discrepancies.
Data from the final 60% of the sample was extracted by
one reviewer, who had participated in all previous steps.
As it was anticipated that there would be a small num-
ber of published SR protocols, it was decided that all
eligible protocols identified during screening would be
prioritized for full-text extraction.
Data collection form
The data extraction form contained three sections as
follows: (i) study characteristics, (ii) whether the review
or protocol fulfilled the reporting criteria in the potential
child-centric modifications/extensions to PRISMA and
PRISMA-P, and (iii) examples of good item reporting.
Many of these details can be found within the Data
Collection form in Additional File 3 and the SR
Decision-Making Criteria Table in Additional File 4.
First, study characteristics were extracted, specifically
the following: year of publication, country of origin,
primary study design, age range of study participants,
diagnoses of study participants and information on
participants, intervention, comparator, and outcomes.
Second, papers were evaluated on whether they reported
on the potential child-centric modifications/extensions
to PRISMA. Some potential extension and modification
items require that certain information be extracted from
single sections (e.g., Discussion) while others allow for
information to be extracted from multiple sections (e.g.,
Abstract and/or Introductory paragraphs) of the in-
cluded papers. Not every PRISMA and PRISMA-P item
has a modification or a corresponding extension item,
and a few have more than one potential extension per
item. This means that the original PRISMA items 5, 7, 9,
10–12, 15, 17, 19, 20, and 22 and PRISMA-P items 1, 2–
4, 9, 11–14, 16, and 17 do not have any potential modifi-
cations or extensions; hence, they were not evaluated in
our evidence synthesis.
For these assessments, the criteria and definition for
each “Yes/Incomplete/No/Not Applicable” response for
each item are detailed in Additional File 4 with corre-
sponding results. For a modified item to be scored as a
“Yes,” both the original item of PRISMA/PRISMA-P and
the potential child-centric items needed to be addressed.
If either the original item or modified text was not
addressed, it was considered as incomplete. The “Incom-
plete” responses of four modified items received further
analysis to assess whether the child-centric criteria were
met even if the PRISMA/PRISMA-P were not. For
child-centric extension items, the full content of the
child-centric potential modification/extension needed to
be addressed in order to be evaluated as a “Yes.”
Partially reported information was classified as “Incom-
plete.” If the item (modification or extension) was not
addressed at all, it was scored as a “No.” Instances where
modification and extension items did not apply to a proto-
col or report were thus marked as “Not Applicable.”
Analysis
The proportion of “Yes” and “Incomplete” responses out
of all eligible articles was presented for each individual
item. The proportion of “No” responses would add to a
total of 100% hence was not presented. Instances where
items were marked as “Not Applicable” were neither
counted in the numerator nor the denominator. We also
provided 95% confidence intervals for each percentage
based on the Wilson-Newcombe method without a
continuity correction [37, 38]. Per item, quality of
reporting was assessed on the basis of whether one third,
one to two thirds, or more than two thirds of reviewed
papers met the reporting requirements of that item. The
proportion of “Yes” responses for each reporting item
was further examined via two subgroup analyses, by type
of review (i.e., Cochrane and non-Cochrane) and by the
targeted population (child-only, mixed child and adult,
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and maternal/family). Pearson’s chi-squared test was
used to determine whether any statistically significant
differences (p < 0.05) existed across groups. Reports and
protocols for similar items were also compared.
Results
The PRISMA flow diagram in Fig. 1 demonstrates the
process used to identify, screen, and select eligible re-
ports and protocols for the SR. Our search identified a
total of 8880 references (4269 from CDSR, 3590 from
DARE, 1021 from MEDLINE/EMBASE). The screening
of titles and abstracts identified 5399 ineligible or dupli-
cate abstracts. All of these were excluded, leaving a set
of 3481 eligible studies; the full-text articles of which
were retrieved for this full set. Of the eligible set, 414
reports and protocols underwent full-text review, 90 of
which did not meet the eligibility criteria. The final tally
of included reports and protocols for the analysis was
324, with 248 reports and 76 protocols (see Additional
File 5 for references) in total; the characteristics of which
are summarized in Table 1. We present the results of
each SR separately in this section.
Systematic review and meta-analysis reports
The results for our review pertaining to SR and MA
reports are displayed in Table 2. The majority of these
248 articles (60.9%) were “child-only studies,” followed
by “mixed child/adult studies” (25.8%) and “maternal/
family studies” (13.3%). In addition, most of these papers
were Cochrane reviews (59.7%). Pharmaceutical drugs/
natural health products (including vitamin supplementa-
tion and herbal remedies) as a group were the interven-
tion (49.2%) and/or comparator (43.5%) of interest in up
to half of the SRs and MAs. SR reports generally focused
on conditions affecting the respiratory system (12.1%),
mental and behavioral disorders (11.3%), pregnancy/
Fig. 1 PRISMA flow diagram depicting flow of information through the different phases of both reviews
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childbirth outcomes (11.3%), and infectious and parasitic
diseases (10.5%).
Title and abstract
Under two thirds (62.1%; 95% confidence interval 56 to
68%) of SRs/MAs, explicitly identified themselves as
such in the title, while also stating their targeted
pediatric age group (Item 1). Child-only studies were sig-
nificantly more likely to declare this information than
family/maternal studies and mixed child/adult studies
(78.8%; 71.6 to 84.6% vs. 54.5; 37.9 to 70.1 and 26.6%;
17.3 to 38.5% p < 0.01).
A minority of papers (9.3%; 6.3 to 13.6%) (i) fulfilled
the original PRISMA recommendations (provide back-
ground, objectives, data sources, etc.), (ii) specified the
targeted pediatric age group (using a unit of time such
as weeks, months, or years), and (iii) stated their primary
and secondary outcome(s) (Item 2). Cochrane papers,
however, were more likely to comply with this recom-
mendation than non-Cochrane papers (16.0%; 10.1 to
24.4 vs. 4.7%; 2.3 to 9.4% p < 0.01).
Table 1 Characteristics of included newborn and child health
systematic review (SR) reports and protocols
Characteristic SR reports % (n) SR protocols % (n)
Total number of studies 248 76
Population included
Child-only studies 60.9 (151) 53.9 (41)
Mixed child/adult studies 25.8 (64) 31.6 (24)
Community/family/maternal
intervention/exposure studies
13.3 (33) 14.5 (11)
Type
Cochrane 59.7 (148) 34.2 (26)
Non-Cochrane 40.3 (100) 65.8 (50)
ICD-10 diagnostic category
Infectious disease and parasitic
diseases
10.5 (26) 15.8 (12)
Neoplasms (including oncology) 2.0 (5) 3.9 (3)
Blood, blood-forming organs,
and the immune mechanism
1.2 (3) 2.6 (2)
Endocrine and nutritional and
metabolic disease
9.7 (24) 7.9 (6)
Mental and behavioral disorders 11.3 (28) 11.8 (9)
Nervous system 4.8 (12) 6.6 (5)
Eye and adnexa 0.4 (1) 0.0 (0)
Ear and mastoid process 1.6 (4) 1.3 (1)
Circulatory system 1.2 (3) 1.3 (1)
Respiratory system 12.1 (30) 1.3 (1)
Digestive system 6.0 (15) 3.9 (3)
Skin and subcutaneous tissue 0.8 (2) 0.0 (0)
Musculoskeletal system and
connective tissue
1.2 (3) 2.6 (2)
Genitourinary, childbirth, and
the puerperium
11.3 (28) 3.9 (3)
Conditions originating in the
perinatal period




2.4 (6) 2.6 (2)
Symptoms, signs, and abnormal
clinical laboratory findings not
elsewhere classified




5.2 (13) 7.9 (6)
External causes of morbidity
and mortality
0.0 (0) 0.0 (0)
Factors influencing health status
and contact with health
services
0.8 (2) 10.5 (8)
Oral health 0.0 (0) 0.0 (0)
No explicit medical condition 8.1 (20) 5.3 (4)
Other 0.4 (1) 2.6 (2)
Intervention type
Table 1 Characteristics of included newborn and child health
systematic review (SR) reports and protocols (Continued)
Drug/natural health products 49.2 (122) 36.8 (28)
Device 8.5 (21) 2.6 (2)
Surgery or radiotherapy 7.7 (19) 7.9 (6)
Rehabilitation or psycho-social 14.5 (36) 9.2 (7)
Vaccine 0.8 (2) 2.6 (2)
Communication, organizational,
or education
9.7 (24) 22.4 (17)
Prevention or screening 2.4 (6) 3.9 (3)
Complex intervention
(>1 interventions)
2.4 (6) 2.6 (2)
Other 5.6 (14) 17.1 (13)
No explicit exposure or
intervention
5.2 (13) 5.3 (4)
Comparison type
Drug/natural health products 43.5 (108) 31.6 (24)
Device 7.3 (18) 2.6 (2)
Surgery or radiotherapy 4.8 (12) 5.3 (4)
Rehabilitation or psycho-social 9.7 (24) 6.6 (5)
Vaccine 0.8 (2) 2.6 (2)
Communication, organizational,
or education
5.2 (13) 14.5 (11)
Prevention or screening 0.8 (2) 2.6 (2)
Complex intervention
(>1 interventions)
2.0 (5) 0.0 (0)
Other 8.1 (20) 15.8 (12)
No explicit exposure or
intervention
26.2 (65) 28.9 (22)
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In mixed child/adult reports, less than a third of arti-
cles (11.6%; 6.0 to 21.3%) provided a structured descrip-
tion of a subgroup analysis for their targeted pediatric
age group (Item 2a). With respect to statements on the
applicability of their results to their targeted pediatric
age group(s), 62.1%; 55.9 to 67.9% of studies met this
item (Item 2b). Of the three intervention groups, how-
ever, we found that child-only studies were significantly
more likely to state the limits of applicability than mixed
child/adult studies and family/maternal studies (75.5%;
68.1 to 81.7 vs. 35.9%; 25.3 to 48.1 vs. 51.5%; 35.2 to
67.5%, p < 0.01)
Introduction
Only 3.6%; 1.9 to 6.7% of reports provided a rationale
for synthesizing evidence for the targeted pediatric age
group(s) and providing hypotheses related to said
group(s) (Item 3a). When reports were not required to
state hypotheses, reporting improved—with more than
two thirds of papers and then meeting this item’s re-
quirements (64.5%; 58.4 to 70.2%). Very few papers
(0.8%; 0.2 to 2.9%) stated their targeted pediatric age
group (in units of time) within an explicit objective(s)
statement (Item 4).
Methods
Nearly all items reported less than one- or two thirds
compliance, except for two potential child-centric items
which received more than two thirds compliance in the
literature.
Eligibility criteria Within the Methods, PRISMA en-
courages SRs and MAs to unambiguously describe the
eligibility criteria used in the review—stating important
details such as study characteristics (e.g., PICOS, length
of follow-up) and report characteristics (e.g., years con-
sidered, language, publication status), while providing a
rationale. More than two thirds of papers (74.2%; 68.4 to
79.2%) justified choosing their selected pediatric age
group (Item 6a). Overall, however, child-only and family/
maternal studies were more apt to meet this expectation
than mixed child/adult studies (88.7%; 82.7 to 92.8%,
84.8%; 69.0 to 93.3 vs. 34.4%; 23.9 to 46.6% p < 0.01).
More than two thirds of reports (67.7%; 61.6 to 73.2%)
justified the intervention for the targeted age group
while addressing age-related differences in intervention
effects (Item 6b), while less than one third provided a ra-
tionale for extrapolating or adapting adult interventions
if done (29.6%; 15.8 to 48.5%, Item 6c). Child-only stud-
ies and family/maternal studies performed considerably
better at justifying interventions than mixed child/adult
studies (87.9%; 72.7 to 95.2 and 78.1%; 70.9 to 84.0 vs.
32.8%; 22.6 to 45.0% p < 0.01). While 40.0%; 21.9 to
61.3% of child-only reports discussed rationales for
adapting adult interventions for their targeted pediatric
age group; no mixed child/adult studies or family/mater-
nal studies fulfilled this criterion (p = 0.037).
Less than a tenth (9.7%; 6.6 to 14.0%) of papers pro-
vided justification of the selected comparators for tar-
geted pediatric age groups (Item 6d). Primary outcomes
were listed and defined in less than half of reports
(41.1%; 35.2 to 47.3%, Item 6e) though Cochrane papers
were significantly more likely to fulfill this goal than
non-Cochrane papers (57%; 47.2 to 66.3 vs. 30.4%; 23.6
to 38.2% p < 0.01). Child-only studies and family/mater-
nal studies were significantly more likely to complete
this requirement than mixed child/adult studies as well
(51.7%; 43.8 to 59.5 and 51.5%; 35.2 to 67.5% vs. 10.9%;
5.4 to 20.9% p < 0.01).
The clinical relevance of selected outcomes for the tar-
geted pediatric age groups was discussed in a third of
papers (34.3%; 28.7 to 40.4%, Item 6f), while the validity,
feasibility, and responsiveness were not discussed to-
gether in any of the published papers (Item 6g). Only
when stratifying by population did we find that clinical
relevance was most often discussed in child-only studies,
followed by family/maternal studies, and discussed the
least in mixed child/adult studies (40.4%; 32.9 to 48.4%
vs. 33.3; 19.7 to 50.36 vs. 20.3%; 12.3 to 31.7% p = 0.018).
Search strategy The potential child-centric reporting
items could recommend that reports describe their
search strategy and corresponding terms within the
Methods (Item 8a), whether it includes database-specific
MeSH terms for pediatric populations used to address
the targeted pediatric age group(s), and whether OR is
used (to enhance sensitivity) or AND (to increase speci-
ficity). Less than half of studies included child-centric
search terms (44.0%; 38.0 to 50.2%), with child-only
studies most likely to include these search terms (60.3%;
52.3 to 67.8%) followed by family/maternal studies
(48.5%; 32.5 to 64.8%) and mixed child/adult studies
being least likely to do so (3.1%; 0.9 to 10.7%) (p < 0.01).
Summary measures and synthesis of results In SRs
and MAs where eligible studies include both adults
and children, our potential child-centric modifications/
extensions to PRISMA recommend that authors provide
summary measures for the adult and targeted pediatric
age group(s) separately (Item 13a). Identified reports
presented far less than one-third compliance with this
item, with only 2.2%; 0.6 to 7.8% of papers meeting this
recommendation. Mixed child/adult studies were more
likely to meet this recommendation than family/maternal
studies (3.2%; 0.9 to 10.9 vs. 0%; 0 to 12.9%, p < 0.01).
For reviews that include studies with mixed/child pop-
ulations yet did not present pediatric results separately,
our potential child-centric modifications/extensions to
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PRISMA recommend that reports provide justification
for why the data for adult and children were combined
(Item 14a); none of the reports met this recommendation.
Additional analyses The last recommendation of our po-
tential child-centric modifications/extensions to PRISMA
concerning Methods reporting is to describe whether ana-
lyses relating to the target pediatric age groups were done
and state the reasons why or why not (Item 16). Less than
two thirds of papers met this item, with 54.9%; 46.7 to
62.8% of papers meeting the recommendation. Cochrane
reviews, however, were significantly more likely to fulfill this
criterion than non-Cochrane reviews (64.1%; 53.9 to 73.2
vs. 38%; 25.9 to 51.8%, p < 0.01). Mixed child/adult studies
most often stated their plan to do a subgroup analysis for
their targeted pediatric age group (68.9%; 54.3 to 80.5%),
followed by child-only studies (54.1%; 42.8 to 65.0%); with
family/maternal studies being least likely to do so (30.4%;
15.6 to 50.8%) (p < 0.01).
Results
Study characteristics Each study in a SR or MA for
which data has been extracted should have their charac-
teristics (e.g., study size, PICOS, follow-up period) pre-
sented alongside the citations (Item 18a). Our potential
child-centric modifications/extensions to PRISMA fur-
ther recommend that the sample size of each pediatric
group and subgroup be stated. Reporting of this aspect
of the potential child-centric PRISMA extension was
found in 72.6%; 66.6 to 77.9% of reports. Child-only
studies and family/maternal studies were most likely to
do this compared to mixed child/adult studies (83.6%;
76.7 to 88.7%, 81.5%; 63.3 to 91.8 vs. 42.6%; 31.0 to
55.1%, p < 0.01).
Synthesis of results For MAs, it is recommended that
the confidence intervals and measures of consistency be
presented. In addition, our potential child-centric modi-
fications/extensions to PRISMA purport that the num-
ber of included studies with pediatric participants, the
number of events concerning children, and the total
pediatric population on which the results synthesis is
based, including age-subgroups, be stated as well (Item
21a). Here, 60.7%; 53.2 to 67.8% of reports meet this
criterion. Cochrane papers were significantly more likely
to meet this reporting recommendation (70.5%; 59.6 to
79.5%) than non-Cochrane papers (52.2%; 42.0 to 62.2%,
p = 0.018). Child-only studies and family/maternal stud-
ies were more likely to meet this recommendation than
mixed child/adult studies (79.0%; 70.0 to 85.8% and
68.4%; 46.0 to 84.6 vs. 20.4; 11.5 to 33.6%, p < 0.01).
Additional analyses Regarding the propensity for which
papers reported the results of additional analyses for
their targeted pediatric age groups (Item 23), 54.0%; 43.6
to 64.1% of papers met this recommendation. Cochrane
reviews and MAs were significantly more likely to report
the results of additional analyses than non-Cochrane papers
(65.1%; 50.7 to 77.2% vs. 43.2%; 29.7 to 57.8% p = 0.046).
Discussion
Summary of evidence In general, 74.5%; 68.6 to 79.6%
of studies are summarizing the main findings of each of
their main outcomes and considering their relevance to
key stakeholders such as healthcare providers, users (i.e.,
children and their families), and policy makers (Item 24).
Compared to mixed child/adult studies (48.4%; 36.4 to
60.6%), child-only studies (83.8%; 77.0 to 88.9%) and
family/maternal studies (82.8%; 65.5 to 92.4%) performed
significantly better (p < 0.01).
Limitations Overall, 35.8%; 29.9 to 42.2% of studies dis-
cussed their limitations at the included study, child
health outcome and review levels (e.g., lack of research
in children, lack of growth, and development outcomes)
(Item 25), with child-only studies (46.9%; 39.0 to 55%)
performing significantly better than family/maternal
studies (19.2%; 8.5 to 37.8%) and mixed child/adult stud-
ies (16.4%; 9.2 to 27.6%) (p < 0.01).
Conclusions
The penultimate potential child-centric modification/ex-
tension recommendation is that concluding statements
give a general interpretation of the results in the context
of “other evidence” (e.g., evidence from adult studies and
pre-clinical studies) and state implications for future re-
search in practice or policy related to the targeted
pediatric age group(s) (Item 26). Overall, this was found
in 43.9%; 37.8 to 50.2% of reports. Less than two thirds
of family/maternal studies (54.8%; 37.7 to 70.8%), and
child-only studies (52.7%; 44.7 to 60.5%), fulfilled this re-
quirement, while less than one third of child/adult stud-
ies (17.5%; 10.1 to 28.7%) met this expectation (p < 0.01).
Funding
Finally, authors are asked to include the source of
financial support for each of the studies they included in
their SR/MA (Item 27a). Overall, the proportion of
papers meeting this recommendation was very low at
5.6%; 3.4 to 9.2%.
Systematic review and meta-analysis protocols
The results of our review pertaining to SR and MA
protocols are displayed in Table 3. Data for this SR was
extracted from 76 eligible protocols. A majority of
these addressed child-only intervention/exposure groups
(53.9%) followed by mixed child/adult groups (31.6%);
the majority of eligible protocols (65.8%) were non-
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Cochrane in origin, while over one third of protocols
focused on pharmaceutical drugs and natural health
products as the intervention/comparator of interest.
Methodological quality was planned for assessment in
nearly all protocols (96.1%), though publication bias was
only planned to be assessed in about half of the eligible
protocols (52.6%). A suitable number of conditions and
diseases were represented in this sample, with the largest
group of protocols focusing on infectious and parasitic
diseases (15.8%), mental and behavioral disorders
(11.8%), and factors influencing health status and con-
tact with health services (10.5%).
Title
Title requirements (i.e., Item 1: identify the protocol as a
SR, MA, or both for the pediatric population as a focus
of review were met in 72.4%; 61.5 to 81.2% of protocols.
Cochrane protocols were most likely to have complete
titles (88.5%; 76.8 to 94.7%) than non-Cochrane proto-
cols (64.0%; 44.8 to 79.5%) (p = 0.015). Child-only proto-
cols and family/maternal protocols were significantly
more likely to meet this recommendation than mixed
child/adult protocols (92.7%; 80.6 to 97.5%, 90.9%; 62.3
to 98.4 vs. 29.2%; 14.9 to 49.2%, p < 0.01).
Support
The proportion of protocols which planned to provide
information on the source of financial support for each
included trial (Item 5d) was small—with 13.2%; 7.3 to
22.6% of protocols intending to provide this information.
This requirement was significantly more likely to be met
by protocols within the Cochrane database than that
within non-Cochrane protocols (30.8%; 19.8 to 44.6 vs.
4.0%; 0.7 to 19.1%, p = 0.01).
Introduction
Rationale and objectives Protocols, much like reviews,
did not tend to provide a rationale for synthesizing evi-
dence in their targeted pediatric age group nor provide
an accompanying hypothesis (Item 6a). This item was
met in less than one third of protocols, with 1.3%; 0.2 to
7.1% meeting this recommendation. When the require-
ment to state hypotheses was rescinded, 87.6%; 78.3 to
93.2% conformed to this item, considerably improving
reporting. All protocols failed to state their targeted
pediatric age group (in units of time) within an explicit
objective(s) statement (Item 7).
Methods
Overall, Methods sections of protocols saw one to two
thirds compliance, except for one child-centric potential
modification for PRISMA-P. Protocols failed to ad-
equately state vital details of and provide a rationale for
each of the choices made in the design of the study.
Eligibility criteria In 64.5%; 53.3 to 74.3% of protocols,
the targeted pediatric age group was justified (Item 8a).
Cochrane database protocols (84.6%; 72.2 to 92.1%) were
more likely to meet this item than non-Cochrane
protocols (54.0%; 35.6 to 71.4%) (p < 0.01). Child-only
protocols (78.0%; 63.2 to 88.0%) were most likely to
meet this recommendation, followed by family/maternal
studies (54.5%; 28.0 to 78.7%), while mixed child/adult
studies (45.8%; 27.9 to 64.9%) met this criterion least
often (p = 0.022). Justification for the intervention for
the targeted pediatric age group (Item 8b) was found in
55.3%; 44.1 to 66.0% of protocols. Cochrane database
protocols (76.9%; 63.6 to 86.4%) were more likely to
meet this criterion than non-Cochrane protocols (44.0%;
26.9 to 62.6%) (p < 0.01). Overall, we found that when
done, only 16.7%; 5.9 to 39.3% of eligible protocols
provided a rationale for extrapolating or adapting adult
interventions for children (Item 8c), and that, only
17.1%; 10.3 to 27.1% of protocols explained their choice
of comparator and provided evidence for the usage of that
comparator in a targeted pediatric age group (Item 8d).
Less than two thirds of protocols reported primary
outcomes and their definition (Item 8e), with just over
half of protocols (55.3%; 44.1 to 66.0%) presenting their
outcomes in this manner. Cochrane protocols were sig-
nificantly more likely to fulfill this need (80.8%; 67.9 to
89.4%) than non-Cochrane protocols (42.0%; 25.3 to
60.8%) (p < 0.01). Child-only protocols and family/mater-
nal protocols outperformed mixed child/adult protocols
(78%; 60.05 to 85.7 and 63.6%, 35.1 to 84.6 vs. 12.5%; 4.3
to 31.0% p < 0.01). The clinical relevance of selected
outcomes for the targeted pediatric age groups was dis-
cussed (Item 8f) in under a third of papers (28.9%; 19.9
to 39.9%), while the validity, feasibility, and responsive-
ness were not discussed together (Item 8g) in any of the
published papers.
Search strategy With respect to the issue that protocols
detail a draft of their search strategy for at least one
electronic database, detailing whether it includes data-
base specific MeSH terms for pediatric populations used
to address the targeted pediatric age group(s), and
whether OR is used (to enhance sensitivity), or AND
(to increase specificity), (our Item10a), less than half
(48.7%; 37.8 to 59.7%) of protocols provided a search strat-
egy with child-centric search terms. When comparing
intervention groups, however, child-only intervention
protocols (63.6%; 35.3 to 84.8%) and family/maternal pro-
tocols (58.5%; 43.3 to 72.2%) were significantly more likely
to meet this recommendation than mixed child/adult
protocols (25.0%; 12.0 to 44.9%) (p = 0.017).
Data synthesis and additional analyses Wherever a
proposed SR or MA could potentially include studies
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featuring child and adult populations without subgroup-
ing, our potential child-centric modifications/extensions
to PRISMA-P also recommend that the protocol states
how that data would be analyzed (Item 15b). As with
evidence synthesis, we found that none of the protocols
met this recommendation. Finally, where any additional
analyses were to be performed regarding a pediatric
age group, our potential child-centric modifications/
extensions to PRISMA-P call for a description of how
the sub-analyses are to be performed (Item 15c). This
item was considered fulfilled in 61%; 48.2 to 72.4% of
protocols.
Systematic reviews reports vs. systematic review
protocols
Table 4 compares the reporting of SR reports and
protocols when assessed by the child-centric potential
modifications/extensions to PRISMA and PRISMA-P.
We found there were only three areas where there was a
statistically significant difference between the reporting
quality of reports and protocols. First, reports were more
likely to justify the intervention for the targeted pediatric
age group(s) (while addressing potential age-related dif-
ferences in intervention effects (potential PRISMA Item
6b/potential protocol PRISMA Item 8b) (67.7%; 61.6 to
73.2 vs. 55.3%; 44.1 to 66.0%, p = 0.047). Second, proto-
cols were more likely to list and define all primary
outcomes for the targeted pediatric age group (potential
Item 6e/potential protocol Item 8e) (55.3%; 44.1 to 66.0
vs. 41.1%; 35.2 to 47.3% p = 0.031). Finally, protocols
were more likely to report (or plan to report) the sources
of funding for each trial within the SR or MA (potential
Item 27a/potential protocol Item 5a) (13.2%; 7.4 to 22.6
vs. 5.6%; 3.4 to 9.2% p = 0.03).
Discussion
We found a relatively incomplete reporting of child-
centric study details across SRs and MAs on interven-
tion studies in children published between 2010 and
2014. Studies with mixed child and adult populations
were significantly more likely to demonstrate incomplete
reporting relative to other groups. In SRs and MAs
where both children and adults are to be included, it
appears necessary that children be analyzed separately in
subgroups. Our results reaffirmed previous evidence that
Cochrane reviews uphold a higher standard of reporting
over other SR publications in general. We did not find
significant differences in reporting quality between SR
reports and protocols. There are currently no child-
centric guidelines that can account for the complexities
associated with the design, implementation, and report-
ing of SRs and MAs in neonates and children [31].
Taken together, we identified a large degree of incom-
plete reporting of both reports and protocols—thereby
highlighting the need for child-centric reporting guide-
lines. The results of this work provide an evidence
foundation for developing child-centric PRISMA-C and
PRISMA-PC guidelines.
Overall quality and completeness of reporting
Incomplete reporting on child-centric topics was a trend
across all reports and protocols, with SR titles being the
only aspect of reporting to be seen in more than two
thirds of papers. Overall, Abstract and Introduction
sections were consistently incomplete, while Methods
were more heterogeneous. Regardless of whether reports
or protocols were being assessed, the majority of the
Methods sections were incompletely reported on child-
centric topics. Results and Discussions were slightly bet-
ter. Reporting on funding was uncommon. A recent
evaluation of the quality of reporting of SRs identified
that while the number of published SRs has increased
threefold since 2004, the overall quality of reporting
have not improved substantially [39].
Our findings are consistent with earlier studies that
demonstrated incomplete reporting quality of SR ab-
stracts in general or adult populations, whereas the
directionality of a determinant-outcome effect could not
be determined from one in four abstracts from the gen-
eral and specialty medical literature [40]. The dearth of
quality reporting in research in children has been
observed numerous times, yielding repeated calls for
child-centric reporting guidelines in the literature [3, 18,
19, 29]. A similar conclusion was reached in a SR
assessing issues in the design, reporting, and conduct of
clinical trials in children [29]. To address these
challenges, 8 and 14 child-centric items were added to
the Standard Protocol Items for Randomized Trials in
Children (SPIRIT-C) and Consolidated Standards of
Reporting Trials in Children (CONSORT-C), respect-
ively [29]. Taken together, our findings indicate that
overall reporting can be improved with the following
areas needing improvement the most: (i) adequate de-
scription of the targeted pediatric (sub)populations in
the Abstract; (ii) explicit rationales and objectives for the
targeted pediatric age groups in Introduction; and (iii)
details on how data on various targeted pediatric age
groups are analyzed in Methods and Results. Finally,
provision of information on the sources of financial sup-
port for each trial in the SR would be helpful. Improving
reporting among these areas for improvement would
also reflect an improvement in the methodological
quality of SRs and MAs. This is acknowledged by the
PRISMA Statement—when assessing study quality, the
distinction between reporting and methodological qual-
ity is less straightforward for SRs than for individual
studies because the reporting and conduct of SRs are
closely intertwined [14].
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Table 4 Comparison of overall reporting quality of newborn and child health systematic review (SR) reports vs. protocols
Proportion (%) of “Yes” responses for the total (no.) of reviews eligible for scoring






1/1a) Identify the report as a systematic review, meta-analysis, or both for pediatric
population as a focus of review, if applicable
62.1 (248) 72.4 (76) 0.102
Introduction
Rationale
5/6) Describe the rationale for the review in the context of what is already known
In the contexts of the synthesized evidence in adults or other pediatric
groups (non-targeted), explain the rationale for synthesizing evidence for
the targeted pediatric age group(s). Provide hypotheses that relate to the
targeted pediatric age group(s)
3.6 (248) 1.3 (76) 0.309
Objectives
4/7) Provide an explicit statement of questions being addressed with reference to
targeted pediatric age groups, interventions, comparisons, outcomes, and
study design (PICOS)
0.8 (248) 0 (76) 0.433
Methods
Eligibility criteria
6/8) Specify study characteristics (e.g., PICOS, length of follow-up) and report
characteristics (e.g., years considered, language, publication status) used as
criteria for eligibility, giving rationale
6a/8a) Justify the targeted pediatric age group(s) selected 74.2 (248) 64.5 (76) 0.1
6b/8b) Intervention: Justify the intervention for the targeted pediatric age
group(s) addressing potential age-related differences in intervention
effects
67.7 (248) 55.3 (76) 0.047*
6c/8c) Provide rationale for extrapolation or adaptation of adult intervention,
if any
29.6 (27) 16.7 (18) 0.331
6d/8d) Comparators: Explain the choice of comparator(s) and, if applicable,
evidence for the active comparator and/or standard of care for
targeted pediatric age group(s)
9.7 (248) 17.1 (76) 0.076
6e/8e) Outcomes: List and define all the primary outcomes addressed for
the targeted pediatric age group(s). List and define growth and
development outcomes, adverse outcomes (events), if applicable
41.1 (248) 55.3 (76) 0.031*
6f/8f) Outcomes: Explain the clinical relevance of the selected outcomes
(benefits and harms) for the targeted pediatric age group(s)
34.3 (248) 28.9 (76) 0.388
6g/8g) Outcomes: Explain the validity, feasibility and responsiveness of
the outcome measures for the pre-targeted pediatric age group(s)
0 (248) 0 (76) p > 0.999
Search
8/10) Present full electronic search strategy for at least one database, including any
limits used, such that it could be repeated
8a/10a) Describe the search strategy and terms (including database specific
MeSH terms for pediatric population) used to address the targeted
pediatric age group(s)
44 (248) 48.7 (76) 0.469
Synthesis of results
14/15b) Describe the methods of handling data and combining results of studies,
if done, including measures of consistency (e.g., I2) for each meta-analysis
14a/15b) For studies that included pediatrics and adults without a subgroup
analysis of the pediatric population, describe how the data on
targeted pediatric age group(s) were used in the analysis
0 (89) 0 (27) p > 0.999
Additional analyses
16/15c) Describe methods of additional analyses (e.g., sensitivity or subgroup analyses
for targeted pediatric age group(s), meta-regression), if done, indicating
which were pre-specified
54.9 (142) 61 (59) 0.429
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Quality of reporting by population
Of the intervention/exposure groups investigated
throughout this review, mixed population studies that
include both children and adults were the least likely to
explicitly report their work for children and adults. In
most reporting areas, mixed child/adult studies showed
less than one third compliance, while child-only and
family/maternal groups performed considerably better.
For example, among both reports and protocols, mixed
child/adult studies were the least likely to list and define
all the primary outcomes addressed for their targeted
pediatric age groups. Also, among the eligible reports,
mixed child/adult SRs were least likely to report the
sample sizes of the pediatric subgroups for each included
study. These results are similar to those in a report
showing it was not possible to determine the ages of trial
participants in a large proportion (35%) of SRs [20]. In-
adequate reporting of age groups hinders the ability to
draw inferences about the different age groups based on
the synthesized evidence [41]. Altogether, these results
suggest a lack of awareness in the literature on the fun-
damental dissimilarities between children and adults and
the importance of differentiating between age and devel-
opmental strata when performing research. To ensure
that age-related differences are accounted for, reports
and publications that include mixed populations would
benefit the most from child-centric reporting guidelines.
Quality of reporting in Cochrane Reviews
Though overall reporting quality remained low, we
found somewhat better quality reporting in Cochrane
reports and protocols. In general, reporting of Cochrane
reports varied, with instances of better reporting in the
Abstract, Methods, and Results sections. Cochrane pro-
tocols have strong Titles, Funding information, and
Methods sections. However, for most of the potential
child-centric modifications/extensions items, however,
there were no statistically significant differences between
Cochrane and non-Cochrane reviews. Reports of higher
quality reporting in Cochrane reviews are not new; when
using PRISMA, QUORUM, and AMSTAR to assess
reporting quality, Cochrane reviews were found to
perform well in general [39] as well as in numerous
health disciplines and age groups, including neonatology
[42], orthodontics [43], otolaryngology [44], physiother-
apy [45], and pediatric dentistry [46, 47]. Taken together,
while there is evidence of better reporting, there is still
much room for improvement within Cochrane child
health SR reports and protocols overall.
Quality of reporting between protocols and reports
Reporting quality of SR reports and protocols was gener-
ally the same, though protocols performed better in two
important aspects of the potential child-centric modifi-
cations/extensions to PRISMA; protocols were signifi-
cantly more likely to justify interventions for the
targeted pediatric age groups and to list and define pri-
mary outcomes addressed for the targeted pediatric age
groups. While the prevalence of funding source report-
ing was low in reports, protocols were more likely to
state their intention to report this information than re-
ports. Further subgroup analysis of protocols found that
Cochrane protocols stated their intention to report this
information more often than non-Cochrane protocols.
This suggests that while there is still considerable room
for improvement, we may see a growing percentage of
reports with this information included, especially if the
Cochrane reports follow the plans laid out in their
protocols.
In summary, the results of our reviews confirm a need
for child health specific reporting extensions for PRISMA
and PRISMA-P with modifications and new items in most
areas of these two existing reporting guidelines. The
results of this review provide a knowledge foundation for
the development of these topics in the existing reporting
standards, in the form of (i) Modifications, (i.e., original
items from the PRISMA-P or PRISMA checklists that
have been modified in wording to incorporate child-
centric aspects of reporting) and (ii) Extensions, (i.e.,
new items that do not exist in the original PRISMA/
PRISMA-P checklists and are included as additional child-
centric components for the original items). The results
can also inform accompanying Explanation and Elabor-
ation (E&E) documents. Our next step is therefore to
undertake a comprehensive consensus exercise with meth-
odologists, systematic reviewers, clinicians, and journal
Table 4 Comparison of overall reporting quality of newborn and child health systematic review (SR) reports vs. protocols
(Continued)
Funding
27/5) Describe sources of funding for the systematic review and other support
(e.g., supply of data) and role of funders for the systematic review
27a/5a) For each included trial in a systematic review, indicate (a plan to
include) the source of financial support (such as Government,
Academia or Industry), if any, in the trial(s)
5.6 (248) 13.2 (76) 0.03*
*p-value correspondent to statistical significant at < 0.05
aItem numbers are potential neonatal and child health modification (bold) and extension (a–g) items for PRISMA-C/PC
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editors with a special interest in child health SRs to develop
these guidelines.
While the development of these extensions themselves
seems worthwhile, the process has to include a serious
exploration of avenues to enhance the extent to which
reporting guidelines are likely to actually improve
reporting. As current evidence suggests that PRISMA
has had only a marginal effect on reporting quality of
SRs [39], additional strategies that improve reporting are
needed. These could include an update of the Cochrane
Handbook, pro-active engagement of SR funders and
journal editors publishing SRs, and learned societies and
guideline developers to endorse the use of reporting
standards, all to reduce research waste.
Strengths and limitations
This work has several strengths. Both of our reviews
include published studies from four major databases
(i.e., Cochrane, DARE, MEDLINE, and EMBASE). By
including a variety of papers from a range of disease
areas, interventions, exposures, and patient populations,
we believe that we have presented results that are re-
flective of the quality of current reports and protocols of
SRs and MAs including children. Our findings of incom-
plete reporting therefore appear generalizable to all SRs
and MAs that include pediatric age groups. Second, by
relying on PRISMA and PRISMA-P as the basis for
quality assessment and improvement, we further justified
the need for and legitimacy of these two guidelines while
building a rationale for improved reporting in children.
A limitation, however, could be the restriction of our
search strategy to SRs and protocols published in English
between the years 2010 and 2014. We are therefore unable
to state the effects of language on reporting quality. We
selected the 2010–2014 time span because we wanted to
observe the current reporting quality after the original
PRISMA Statement on reporting quality was released in
2009. Moreover, we searched only CDSR and DARE for
SRs, which is likely to yield higher quality SRs than those
indexed elsewhere. Yet, it highlights the need for a report-
ing standard, given the overall incomplete reporting. An-
other limitation of our reviews is the inherent subjectivity
that lies in assessing the reporting quality of each report
and protocol. Though the reviewers were guided by the ori-
ginal PRISMA and PRISMA-P guidelines as well as exten-
sion and modification items for child relevant SR protocols
and reports, it was challenging to ensure that reports and
protocols received consistent scoring both between reviews
and over the course of data extraction. To account for these
difficulties, we operationalized the requirements for a “Yes,”
“No,” “Incomplete,” and “Not applicable” score for each
modification and extension item (Additional File 4). We
piloted and reviewed the scoring of the first 10% of the
studies to ensure consistency of reviewers’ classification of
each item and discussed any discrepancy in classification.
Conclusions
Newborn and child health SRs and MAs exhibit incom-
plete reporting of child-centric topics. Reports and
protocols with a mixed children/adult population are
more prone to incomplete reporting than child-only
populations, while Cochrane reviews are of a better
reporting standard than non-Cochrane reviews. Overall,
these results provide a rationale for increased adoption
of the PRISMA and PRISMA-P reporting guidelines and
a basis for child-centric extensions and modifications to
these reporting standards to improve the ability of
decision-makers to inform policy and program decisions
for specific age groups.
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